BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122-1129. [PMID: 28315983 DOI: 10.1007/s00535-017-1328-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Zarębska-Michaluk D, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Can J Gastroenterol Hepatol 2019;2019:4029541. [PMID: 30941326 DOI: 10.1155/2019/4029541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. J Med Virol 2020;92:210-8. [PMID: 31584207 DOI: 10.1002/jmv.25602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24:1098-1106. [PMID: 28632923 DOI: 10.1111/jvh.12737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
4 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
5 Takaki S, Imamura M, Yamaguchi S, Fukuhara T, Mori N, Tsuji K, Ohya K, Hayes CN, Aikata H, Chayama K. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol 2020;13:1233-8. [PMID: 32656649 DOI: 10.1007/s12328-020-01182-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 2019;54:916-27. [PMID: 30903385 DOI: 10.1007/s00535-019-01575-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
7 Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48:802-809. [PMID: 29504692 DOI: 10.1111/hepr.13074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
8 Yang S, Xing H, Feng S, Ju W, Liu S, Wang X, Ou W, Cheng J, Pan CQ. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. Arch Virol 2018;163:467-73. [PMID: 29143142 DOI: 10.1007/s00705-017-3640-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
9 Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. J Gastroenterol. 2018;53:548-556. [PMID: 28815329 DOI: 10.1007/s00535-017-1380-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
10 Kawagishi N, Suda G, Kimura M, Maehara O, Yamada R, Tokuchi Y, Kubo A, Kitagataya T, Shigesawa T, Suzuki K, Ohara M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep 2021;11:9207. [PMID: 33911145 DOI: 10.1038/s41598-021-88632-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; for the NORTE Study Group. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study: FLV add-on SMV/Peg-IFN/RBV therapy. Hepatol Res 2018;48:E146-54. [DOI: 10.1111/hepr.12938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Uemura H, Uchida Y, Kouyama JI, Naiki K, Tsuji S, Sugawara K, Nakao M, Motoya D, Nakayama N, Imai Y, Tomiya T, Mochida S. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019;54:459-470. [PMID: 30612205 DOI: 10.1007/s00535-018-01543-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
13 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PLoS One 2018;13:e0198642. [PMID: 29856885 DOI: 10.1371/journal.pone.0198642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Sho T, Suda G, Ogawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Ito J, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Terasita K, Takagi T, Kamiyama T, Taketomi A, Sakamoto N. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. Hepatol Res 2020;50:966-77. [PMID: 32562334 DOI: 10.1111/hepr.13511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
15 Suda G, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. J Gastroenterol 2019;54:78-86. [PMID: 30019127 DOI: 10.1007/s00535-018-1495-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Suda G, Nakai M, Sho T, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Baba M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Intern Med 2019;58:943-7. [PMID: 30568153 DOI: 10.2169/internalmedicine.2077-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, Okada M, Shimizu T, Higuchi M, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. Int J Mol Sci 2020;21:E3640. [PMID: 32455631 DOI: 10.3390/ijms21103640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One. 2018;13:e0209615. [PMID: 30576386 DOI: 10.1371/journal.pone.0209615] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
19 Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatol Res. 2018;48:529-538. [PMID: 29316051 DOI: 10.1111/hepr.13056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
20 Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N;  NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168-180. [PMID: 33211179 DOI: 10.1007/s00535-020-01750-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N. Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Hepatol Res 2019;49:1275-85. [PMID: 31261439 DOI: 10.1111/hepr.13401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N;  NORTE Study Group. Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. Hepatol Res. 2019;49:1294-1304. [PMID: 31260579 DOI: 10.1111/hepr.13399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
23 Sato K, Uraoka T. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. World J Gastroenterol 2018; 24(38): 4304-4310 [PMID: 30344416 DOI: 10.3748/wjg.v24.i38.4304] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol Res 2020;50:453-65. [PMID: 31846553 DOI: 10.1111/hepr.13474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Naganuma A, Sato K, Fukuchi T, Namikawa M, Kakizaki S, Uraoka T, Ohnishi H, Okamoto H. Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report. Clin J Gastroenterol 2019;12:592-7. [PMID: 31376076 DOI: 10.1007/s12328-019-01029-y] [Reference Citation Analysis]
26 Uchida Y, Nakamura S, Kouyama JI, Naiki K, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Hedskog C, Brainard D, Mo H, Mochida S. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Sci Rep 2018;8:8818. [PMID: 29892096 DOI: 10.1038/s41598-018-27291-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
27 Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res 2018;48:233-43. [PMID: 28884930 DOI: 10.1111/hepr.12980] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
28 Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 2018;12:356-67. [PMID: 30030720 DOI: 10.1007/s12072-018-9878-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]